Seres Therapeutics (MCRB) Preferred Stock Liabilities (2014)

Seres Therapeutics (MCRB) posted Preferred Stock Liabilities of $1.6 million for Q4 2014.

Seres Therapeutics (MCRB) Preferred Stock Liabilities (2014) Analysis & Trends

Seres Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $1.6 million in Q4 2014.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.6 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $1.6 million (changed N/A YoY) and the FY2014 annual result came in at $1.6 million, down 86.34% from the prior year.
Preferred Stock Liabilities held at $1.6 million in Q4 2014 per MCRB's latest filing.
Over five years, Preferred Stock Liabilities peaked at $1.6 million in Q4 2014 and troughed at $1.6 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-	-

Download Data

Date	Value
Dec 31, 2014	1.58 Mn